SCHEMBL2483161

SCHEMBL2483161

O=C[C@@H](O)[C@@H](OCc1ccccc1)[C@H](OCc1ccccc1)[C@H](O)COCc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CA1 P00915 4/20 0.45
CA2 P00918 2/20 0.45
CA7 P43166 2/20 0.45
CA9 Q16790 2/20 0.45
KMT2A Q03164 2/20 0.44
MAPK1 P28482 1/20 0.44
SLC1A1 P43005 3/20 0.40
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
MEN1 O00255 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
HTT P42858 1/20 0.40
TACR1 P25103 4/20 0.40
TSHR P16473 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5980669 1.00 CA1 (0.45) CA1CA2CA7CA9KMT2A
SCHEMBL27829633 1.00 CA1 (0.45) CA1CA2CA7CA9KMT2A
SCHEMBL1578761 1.00 CA1 (0.45) CA1CA2CA7CA9KMT2A
SCHEMBL11790408 0.96 CA1 (0.46) CA1CA2CA7CA9KMT2A
Diphenylsulfane SCHEMBL4398858 0.92 CA1 (0.40) CA1CA2CA7CA9KMT2A
SCHEMBL27957107 0.90 CA1 (0.44) CA1CA2CA7CA9KMT2A
SCHEMBL11454462 0.88 CA1 (0.56) CA1CA2CA7CA9KMT2A
SCHEMBL23292518 0.87 CA1 (0.44) CA1CA2CA7CA9KMT2A
SCHEMBL1479599 0.87 CA1 (0.44) CA1CA2CA7CA9KMT2A
SCHEMBL1674203 0.87 CA1 (0.44) CA1CA2CA7CA9KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9493498-B2 Oligosaccharide-protein conjugates GENZYME CORPORATION (US) 2016-11-15 US claimed
US-20150175643-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION 2015-06-25 US claimed
EP-2465542-B1 Oligosaccharide-protein conjugates GENZYME CORP (US) 2015-01-21 EP claimed
US-8835614-B2 Oligosaccharide-protein conjugates GENZYME CORPORATION (US) 2014-09-16 US claimed
EP-2465542-A1 Oligosaccharide-protein conjugates Genzyme Corporation (US) 2012-06-20 EP claimed
US-20110300120-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION 2011-12-08 US claimed
EP-4212541-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES AND THEIR INTERMEDIATES Genzyme Corporation (US) 2023-07-19 EP disclosed
EP-3608330-B1 SYNTHETIC INTERMEDIATES FOR PREPARING OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORP (US) 2022-11-09 EP disclosed
US-20220242899-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION 2022-08-04 US disclosed
US-11279725-B2 Oligosaccharide-protein conjugates GENZYME CORPORATION (US) 2022-03-22 US disclosed
CN-112618724-A Oligosaccharide-protein conjugates 建新公司 2021-04-09 CN disclosed
CN-112220930-A Oligosaccharide-protein conjugates 建新公司 2021-01-15 CN disclosed
US-20200216485-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION 2020-07-09 US disclosed
US-20150175643-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION 2015-06-25 US disclosed
EP-2465542-B1 Oligosaccharide-protein conjugates GENZYME CORP (US) 2015-01-21 EP disclosed
US-8835614-B2 Oligosaccharide-protein conjugates GENZYME CORPORATION (US) 2014-09-16 US disclosed
EP-2465542-A1 Oligosaccharide-protein conjugates Genzyme Corporation (US) 2012-06-20 EP disclosed
US-20110300120-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION 2011-12-08 US disclosed
EP-2376123-A2 OLIGOSACCHARIDE-PROTEIN CONJUGATES Genzyme Corporation (US) 2011-10-19 EP disclosed
WO-2010075010-A2 OLIGOSACCHARIDE-PROTEIN CONJUGATES GENZYME CORPORATION (US) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220242899-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES MAN2B1, GAA, GBA1 CA1 3117/4885CA2 4120/4885CA7 2210/4885
US-20200216485-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES MAN2B1, GAA, GBA1 CA1 3117/4885CA2 4120/4885CA7 2210/4885
US-20110300120-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES MAN2B1, GAA, GBA1 CA1 3117/4885CA2 4120/4885CA7 2210/4885
US-20150175643-A1 OLIGOSACCHARIDE-PROTEIN CONJUGATES MAN2B1, GAA, GBA1 CA1 3117/4885CA2 4120/4885CA7 2210/4885
US-11279725-B2 Oligosaccharide-protein conjugates MAN2B1, GAA, GBA1 CA1 3117/4885CA2 4120/4885CA7 2210/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.